![](https://investorshub.advfn.com/uicon/135615.png?cb=1617431497)
Friday, May 21, 2021 5:19:52 AM
Momentum has been driving PDS Biotech (PDSB) stock forward in 2021 and the latest developments have put more fuel in the tank for this micro-cap biotech.
Shares were trending higher in Thursday’s session following the publication of interim data from the NCI-led Phase 2 study of PDS0101 for the treatment of HPV-related cancers. The company is working on novel cancer therapies based on its proprietary Versamune T-cell activating technology.
The trial is looking into a triple combination of PDS0101 with a pair of investigational immunomodulating agents - bintrafusp alfa (M7824), a TGF-ß trap/anti-PD-L1 bifunctional fusion protein, and NHSIL12 (M9241), a DNA-targeted immunocytokine.
The data from 14 patients showed tumor reductions in 83% of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients (5 of 6) and 63% of HPV16-positive relapsed or refractory advanced cancer patients who also failed to respond to checkpoint inhibitor therapy (5 of 8).
Overall, the objective response rate was 71% (10/14), amongst them 1 complete response (anal cancer) and 9 partial responses (3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal cancer, 2 oropharyngeal cancer). After a median 5 months of follow up, 90% (9 out of 10) of these responses are ongoing.
“We believe these results represent an important validation of Versamune's ability to elicit anti-tumor responses in patients that have received multiple lines of therapy and may present a weakened and unresponsive immune system,” said H.C. Wainwright’s Joseph Pantginis. “On an important note, these results reflect those seen in preclinical studies with the triple combination, therefore adding confidence the positive outcome of these studies.”
Pantginis also make a point of reminding investors that all three PDS0101 “important” Phase 2 studies are now in process with readouts anticipated this year or at the start of 2022.
“We believe the potential news flow from these studies to be meaningful during 2021, and should lead to multiple catalysts representing important drivers for the shares,” the 5-star analyst further noted.
Given the strong data, Pantginis says it is no wonder the company will make an oral presentation – including results from a larger sample base - at the 2021 ASCO Annual Meeting on June 7.
To this end, Pantginis rates PDSB a Buy while his $8 price target suggests 12-month upside of 10%. (To watch Pantginis’ track record, click here)
Pantginis’ colleagues agree. All 4 recent reviews say Buy, naturally culminating in a Strong Buy consensus rating. The average price target clocks in at $9.40, suggesting further upside of 29%.
https://finance.yahoo.com/news/pds-biotech-stock-buy-now-225536278.html
Recent PDSB News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 12:05:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:16:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:33:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 10:10:16 PM
- PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 01/22/2024 09:45:19 PM
- PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/04/2023 09:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:02:38 PM
- PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer • GlobeNewswire Inc. • 11/28/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 11:02:46 AM
- PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 12:30:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:07:59 PM
- PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 08:06:44 PM
- PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:02:24 PM
- PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer • GlobeNewswire Inc. • 10/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:03:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 01:02:10 PM
- PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) • GlobeNewswire Inc. • 10/03/2023 11:00:00 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM